Evergreen Therapeutics Inc.

Moderna, Inc. ’s respiratory syncytial virus vaccine will become the next application to miss its Prescription Drug User Fee Act goal date for a US Food and Drug Administration decision, suggesting th

Although Shanghai Junshi Biosciences Co., Ltd. was considered to have a bigger chance to sail through the FDA approval process, the truth is still heartbreaking for other Chinese drug makers eyeing a